Eulalia Baselga

Eulalia Baselga

Auto-generated profile, based on publicly available information

Eulalia Baselga

Hospital Sant Joan de Déu Barcelona Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MPMilena Petkova
Milena Petkova
MKMarle Kraft
Marle Kraft
SSSimon Stritt
Simon Stritt
IMInes Martinez-Corral
Ines Martinez-Corral
HOHenrik Ortsäter
Henrik Ortsäter
TMTaija Mäkinen
Taija Mäkinen
Oncogenic mutations in PIK3CA, encoding p110α-PI3K, are a common cause of venous and lymphatic malformations. Vessel type–specific disease pathogenesis is poorly understood, hampering development of efficient therapies. Here, we reveal a new immune-interacting subtype of Ptx3-positive dermal lymphatic capillary endothelial cells (iLECs) that recruit pro-lymphangiogenic macrophages to promote progressive lymphatic overgrowth. Mouse model of Pik3caH1047R-driven vascular malformations showed that proliferation was induced in both venous and lymphatic ECs but sustained selectively in LECs of advanced lesions. Single-cell transcriptomics identified the iLEC population, residing at lymphatic capillary terminals of normal vasculature, that was expanded in Pik3caH1047R mice. Expression of pro-inflammatory genes, including monocyte/macrophage chemokine Ccl2, in Pik3caH1047R-iLECs was associated with recruitment of VEGF-C–producing macrophages. Macrophage depletion, CCL2 blockade, or anti-inflammatory COX-2 inhibition limited Pik3caH1047R-driven lymphangiogenesis. Thus, targeting the paracrine crosstalk involving iLECs and macrophages provides a new therapeutic opportunity for lymphatic malformations. Identification of iLECs further indicates that peripheral lymphatic vessels not only respond to but also actively orchestrate inflammatory processes.

1 May 2021 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
FMFania Z. Muñoz-Garza
Fania Z. Muñoz-Garza
MRMónica Ríos
Mónica Ríos
EREsther Roé-Crespo
Esther Roé-Crespo
JBJosé Bernabeu-Wittel
José Bernabeu-Wittel
MMMaría Teresa Montserrat-García
María Teresa Montserrat-García
EBEulalia Baselga
Eulalia Baselga
Importance Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol. To our knowledge, no studies have determined whether beginning early treatment with timolol for IH is better than in other proliferative stages. Objective To evaluate the efficacy and safety of timolol maleate solution, 0.5%, for the early treatment of IH in infants younger than 60 days. Design, Setting, and Participants This multicenter, randomized, double-blind, placebo-controlled, phase 2a pilot clinical trial included patients aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). Patients were randomly assigned to treatment with topical timolol maleate solution, 0.5%, or placebo twice daily for 24 weeks. Changes in lesion size (volume, thickness) and color were evaluated from photographs taken at 2, 4, 8, 12, 24, and 36 weeks. Vital signs and adverse effects were recorded at each visit. The study was carried out from November 2015 to January 2017, and data analyses were completed in September 2019. Main Outcomes and Measures The primary outcome of complete or nearly complete IH resolution and the secondary outcomes of changes in lesion thickness, volume, and color were evaluated by a blinded investigator. Results Of the 69 patients recruited, the mean (SD) age was 48.4 (10.6) days; 55 (80%) were female; and 51 (74%), 11 (16%), 6 (9%), and 1 (1%) had superficial, mixed, abortive, or deep IHs, respectively. The IHs were localized, segmental, or indeterminate in 60 (87%), 7 (10%), and 2 (3%) patients, respectively. The IHs were located on the head and/or neck (n = 23 [33%]) or other body sites (n = 46 [67%]). The study was completed by 26 of 33 (79%) patients receiving timolol and 31 of 36 (86%) receiving placebo. There were no significant differences between timolol and placebo for complete or nearly complete IH resolution at 24 weeks (n = 11 [42%] vs n = 11 [36%];P = .37). The odds ratio of complete or almost complete response vs no response at week 24 was 1.33 (95% CI, 0.45-3.89). There were no between-group differences in IH size (volume, thickness). An improvement in color was observed at week 4 in the timolol group, and timolol was well tolerated with no systemic adverse effects. Conclusions and Relevance In this randomized clinical trial, results demonstrated that topical timolol is well tolerated for the treatment of early proliferative IH but provides limited benefit in lesion resolution when given during the early proliferative stage. Trial Registration EudraCT Identifier:2013-005199-17

13 June 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PKPiotr Kobialka
Piotr Kobialka
HSHelena Sabata
Helena Sabata
OVOdena Vilalta
Odena Vilalta
LGLeonor Gouveia
Leonor Gouveia
AAAna Angulo‐Urarte
Ana Angulo‐Urarte
MGMariona Graupera
Mariona Graupera
Low‐flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K‐driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K‐driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low‐flow vascular malformations.

16 July 2021 in Clinical Genetics
Verified
Journal Article
Open access
PDF file
SDSofia Douzgou
Sofia Douzgou
MRMyfanwy Rawson
Myfanwy Rawson
EBEulalia Baselga
Eulalia Baselga
MDMoise Danielpour
Moise Danielpour
LFLaurence Faivre
Laurence Faivre
LBLeslie G. Biesecker
Leslie G. Biesecker
Growth promoting variants in PIK3CA cause a spectrum of developmental disorders, depending on the developmental timing of the mutation and tissues involved. These phenotypically heterogeneous entities have been grouped as PIK3CA‐Related Overgrowth Spectrum disorders (PROS). Deep sequencing technologies have facilitated detection of low‐level mosaic, often necessitating testing of tissues other than blood. Since clinical management practices vary considerably among healthcare professionals and services across different countries, a consensus on management guidelines is needed. Clinical heterogeneity within this spectrum leads to challenges in establishing management recommendations, which must be based on patient‐specific considerations. Moreover, as most of these conditions are rare, affected families may lack access to the medical expertise that is needed to help address the multi‐system and often complex medical issues seen with PROS. In March 2019, macrocephaly‐capillary malformation (M‐CM) patient organizations hosted an expert meeting in Manchester, United Kingdom, to help address these challenges with regards to M‐CM syndrome. We have expanded the scope of this project to cover PROS and developed this consensus statement on the preferred approach for managing affected individuals based on our current knowledge.

23 April 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
VDVictoria L. Dávila‐Osorio
Victoria L. Dávila‐Osorio
HRHelena Iznardo Ruiz
Helena Iznardo Ruiz
EREsther Roé
Esther Roé
LPLluis Puig
Lluis Puig
EBEulalia Baselga
Eulalia Baselga

16 May 2020 in Pediatric Dermatology
Verified
Journal Article
Open access
PDF file
IFIlona J. Frieden
Ilona J. Frieden
KPKatherine B. Püttgen
Katherine B. Püttgen
BDBeth A. Drolet
Beth A. Drolet
MGMaria C. Garzon
Maria C. Garzon
SCSarah L. Chamlin
Sarah L. Chamlin
FGFor The Hemangioma Investigator Group
For The Hemangioma Investigator Group
The COVID‐19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long‐term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMA‐approved monitoring guidelines, clinical practice guidelines, and relevant, up‐to‐date publications regarding initiation and monitoring of beta‐blocker therapy were used to inform the recommendations. Clinical decision‐making guidelines about when telehealth is an appropriate alternative to in‐office visits, including medication initiation, dosage changes, and ongoing evaluation, are included. The importance of communication with caregivers in the context of telemedicine is discussed, and online resources for both hemangioma education and propranolol therapy are provided.